medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2019, Número 5

<< Anterior Siguiente >>

Rev Mex Urol 2019; 79 (5)


Conducta sexual y otros factores de riesgo para cáncer de próstata

Ángeles-Garay U, Sandoval-Sánchez JJ, Sánchez-Martínez LC, Acosta-Cazares B, Ruíz-Betancourt BS

Idioma: Español
Referencias bibliográficas: 25
Paginas: 1-14
Archivo PDF: 217.33 Kb.


RESUMEN

El cáncer de próstata (cap) es la neoplasia de mayor impacto para población masculina. Los factores conocidos que lo originan son la edad, la raza y la herencia; mientras que otros componentes, como la conducta sexual, no han sido bien establecidos.
Objetivo: Medir la asociación de la conducta sexual y otros factores con el cap en población mexicana.
Materiales y métodos: Se realizó un estudio de casos y controles pareado, en el cual se incluyeron como casos a pacientes con adenocarcinoma de la próstata (AV) y como controles a pacientes sin diagnóstico de cap ± 3 años de edad. Se realizó una entrevista médica confidencial para obtener la información sobre las variables de estudio y se completó de los expedientes hospitalarios.
Resultados: El inicio de vida sexual (IVS) después de los 18 años tuvo una RM de 2.82 (IC95% 1.27-6.25), la soltería RM 16.4 (IC 95% 5.42- 49.65); las relaciones sexuales (RS) con trabajadoras del sexo comercial (TSC) RM 8.75 (IC 95% 3.66-20.9), y el antecedentes de enfermedad de transmisión sexual RM 2.49 (IC 95% 1.24-4.99).
Conclusiones: De las características de la conducta sexual masculina, el inicio de vida sexual tardía, la soltería, RS con TSC y el antecedente de alguna ETS resultaron asociados con el riesgo de padecer cap. No encontramos asociación con el número de parejas sexuales (NPS) ni con la frecuencia de las RS


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lee D, Lee C, Kwon T, You D, Jeong IG, Hong JH, et al. Clinical features and prognosis of prostate cancer with high-grade prostatic intraepithelial neoplasia. Korean J Urol. 2015 Aug;56(8):565–71. doi: https://dx.doi. org/10.4111%2Fkju.2015.56.8.565

  2. Amano K, Maeda I, Shimoyama S, Shinjo T, Shirayama H, Yamada T, et al. The Accuracy of Physicians’ Clinical Predictions of Survival in Patients With Advanced Cancer. J Pain Symptom Manage. 2015 Aug;50(2):139- 146.e1. doi: https://doi.org/10.1016/j. jpainsymman.2015.03.004

  3. Ramírez-Backhaus M, González-Tampán J, Ortiz-Rodríguez IM, Gómez-Ferrer Á, Rubio- Briones J, Collado-Serra A, et al. Urinary tract symptoms and erectile function in patients at risk of prostate cancer. Actas Urol Esp. 2015 Aug;39(6):360–6. doi: https://doi. org/10.1016/j.acuro.2014.10.005

  4. Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA. Long-term Outcomes of Patients with Lymph Node Metastasis Treated with Radical Prostatectomy Without Adjuvant Androgen-deprivation Therapy. European Urology. 2014 Jan 1;65(1):20–5. doi: https:// doi.org/10.1016/j.eururo.2013.03.053

  5. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012 Jun;61(6):1079–92. doi: https:// doi.org/10.1016/j.eururo.2012.02.054

  6. Gómez-Dantés H, Lamadrid-Figueroa H, Cahuana-Hurtado L, Silverman-Retana O, Montero P, González-Robledo MC, et al. The burden of cancer in Mexico, 1990-2013. Salud Publica Mex. 2016 Apr;58(2):118–31. doi: https://doi.org/10.21149/spm.v58i2.7780

  7. Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, et al. Screening for familial and hereditary prostate cancer. Int J Cancer. 2016 Jun 1;138(11):2579–91. doi: https://doi.org/10.1002/ijc.29949

  8. Khani F, Mosquera JM, Park K, Blattner M, O’Reilly C, MacDonald TY, et al. Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin Cancer Res. 2014 Sep 15;20(18):4925–34. doi: https://doi.org/10.1158/1078-0432.CCR- 13-2265

  9. Farrell J, Petrovics G, McLeod DG, Srivastava S. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci. 2013 Jul 25;14(8):15510–31. doi: https://doi. org/10.3390/ijms140815510

  10. Sawada N. Risk and preventive factors for prostate cancer in Japan: The Japan Public Health Center-based prospective (JPHC) study. J Epidemiol. 2016 Nov 15;27(1):2–7. doi: https://dx.doi.org/10.1016%2Fj.je.2016.09.001

  11. Curtis A, Ondracek RP, Murekeyisoni C, Kauffman E, Mohler J, Marshall J. Tobacco use and outcome in radical prostatectomy patients. Cancer Med. 2017 Apr;6(4):857–64. doi: https://doi.org/10.1002/cam4.1041

  12. Vainshelboim B, Müller J, Lima RM, Nead KT, Chester C, Chan K, et al. Cardiorespiratory fitness and cancer incidence in men. Ann Epidemiol. 2017;27(7):442–7. doi: https://doi. org/10.1016/j.annepidem.2017.06.003

  13. Ganesh B, Saoba SL, Sarade MN, Pinjari SV. Risk factors for prostate cancer: An hospitalbased case-control study from Mumbai, India. Indian J Urol. 2011 Jul;27(3):345–50. doi: https://doi.org/10.4103/0970-1591.85438

  14. Pacheco SOS, Pacheco FJ, Zapata GMJ, Garcia JME, Previale CA, Cura HE, et al. Food Habits, Lifestyle Factors, and Risk of Prostate Cancer in Central Argentina: A Case Control Study Involving Self-Motivated Health Behavior Modifications after Diagnosis. Nutrients. 2016 Jul 9;8(7). doi: https://doi.org/10.3390/ nu8070419

  15. Nair-Shalliker V, Yap S, Nunez C, Egger S, Rodger J, Patel MI, et al. Adult body size, sexual history and adolescent sexual development, may predict risk of developing prostate cancer: Results from the New South Wales Lifestyle and Evaluation of Risk Study (CLEAR). Int J Cancer. 2017 Feb 1;140(3):565–74. doi: https://doi. org/10.1002/ijc.30471

  16. Wang Y-C, Chung C-H, Chen J-H, Chiang M-H, Ti-Yin null, Tsao C-H, et al. Gonorrhea infection increases the risk of prostate cancer in Asian population: a nationwide populationbased cohort study. Eur J Clin Microbiol Infect Dis. 2017 May;36(5):813–21. doi: https://doi. org/10.1007/s10096-016-2866-7

  17. Hennis AJM, Wu S-Y, Nemesure B, Leske MC. Urologic characteristics and sexual behaviors associated with prostate cancer in an african- Caribbean population in barbados, west indies. Prostate Cancer. 2013;2013:682750. doi: https://doi.org/10.1155/2013/682750

  18. Plata Bello A, Concepcion Masip T. Prostate cancer epidemiology. Arch Esp Urol. 2014 Jun;67(5):373–82.

  19. Kim SH, Kim S, Joung JY, Kwon W-A, Seo HK, Chung J, et al. Lifestyle Risk Prediction Model for Prostate Cancer in a Korean Population. Cancer Res Treat. 2018 Oct;50(4):1194–202. doi: https://dx.doi.org/10.4143%2Fcrt.2017.484

  20. Vázquez-Salas RA, Torres-Sánchez L, López- Carrillo L, Romero-Martínez M, Manzanilla- García HA, Cruz-Ortíz CH, et al. History of gonorrhea and prostate cancer in a populationbased case-control study in Mexico. Cancer Epidemiol. 2016 Feb;40:95–101. doi: https:// doi.org/10.1016/j.canep.2015.12.001

  21. Bashir MN, Ahmad MR, Malik A. Risk factors of prostate cancer: a case-control study in Faisalabad, Pakistan. Asian Pac J Cancer Prev. 2014;15(23):10237–40. doi: https://doi. org/10.7314/apjcp.2014.15.23.10237

  22. Ballon-Landa E, Parsons JK. Nutrition, physical activity, and lifestyle factors in prostate cancer prevention. Curr Opin Urol. 2018 Jan;28(1):55–61. doi: https://doi.org/10.1097/ MOU.0000000000000460

  23. Sato C, Kaneko S, Sato A, Virgona N, Namiki K, Yano T. Combination Effect of δ-Tocotrienol and γ-Tocopherol on Prostate Cancer Cell Growth. J Nutr Sci Vitaminol. 2017;63(5):349– 54. doi: https://doi.org/10.3177/jnsv.63.349

  24. Stott-Miller M, Wright JL, Stanford JL. MSMB gene variant alters the association between prostate cancer and number of sexual partners. Prostate. 2013 Dec;73(16):1803–9. doi: https:// doi.org/10.1002/pros.22719

  25. Taylor ML, Mainous AG, Wells BJ. Prostate cancer and sexually transmitted diseases: a metaanalysis. Fam Med. 2005 Aug;37(7):506–12.




2020     |     www.medigraphic.com